Cellular Discrepancy of Platinum Complexes in Interfering with Mitochondrial DNA

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Mitochondria are crucial for cellular functions including energy metabolism and cell death.
• Mitochondrial DNA (mtDNA) integrity is vital for mitochondrial function; damage impairs energy production and signaling.
• Platinum-based anticancer drugs often cause nephrotoxicity due to off-target effects.

Purpose of the Study:

• To investigate the effects of a monofunctional trinuclear platinum complex (MTPC) on mitochondrial DNA (mtDNA) in cancerous versus normal cells.
• To evaluate MTPC's potential for cancer therapy by assessing its cytotoxicity and mechanism of action.
• To explore MTPC's ability to overcome the nephrotoxicity associated with conventional platinum drugs.

Main Methods:

• Treatment of human lung cancer A549 cells and human kidney 2 (HK-2) cells with MTPC.
• Assessment of mitochondrial function, including membrane potential, mtDNA copy number, ATP levels, and mitophagy.
• Analysis of MTPC's impact on nucleoid proteins and polymerase gamma gene.
• Investigation of mtDNA release into the cytosol and activation of the cGAS-STING pathway.
• Evaluation of MTPC's cytotoxicity against A549 and HK-2 cells.

Main Results:

• MTPC severely impaired mitochondrial integrity and function in A549 cancer cells, decreasing membrane potential, mtDNA copy number, and ATP levels, while inducing mitophagy.
• MTPC minimally affected mtDNA in normal HK-2 cells, showing significantly lower cytotoxicity.
• MTPC promoted mtDNA release into the cytosol, activating the cGAS-STING pathway and potentially stimulating antitumor immunity.
• The complex demonstrated significant cytotoxicity against A549 cells but weak toxicity toward HK-2 cells.

Conclusions:

• MTPC exhibits selective toxicity towards cancer cells by targeting mitochondrial DNA, offering a potential advantage over conventional platinum drugs by reducing nephrotoxicity.
• The ability of MTPC to induce mtDNA release and activate the cGAS-STING pathway suggests a novel mechanism for triggering anti-tumor immunity.
• Targeting mitochondria presents a significant therapeutic strategy in cancer treatment due to the differential effects observed in cancer versus normal cells.